Brilish dJm o C w (15)71, 587-591 © (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations.
Treatment of gastric cancer remains a great challenge. At diagnosis, 75% of patients have disseminated disease (Dupont et al., 1978) . Even among the subgroup of patients able to undergo potentially curative resection, relapse is common. Because 5 year survival ranges from 10% to 15% of all patients with newly diagnosed disease, the use of chemotherapy in patients with gastric cancer has been the subject of great interest.
At present, four drugs have been identified as exhibiting modest or moderate single-agent activity in patients with advanced gastric cancer. These drugs are 5-fluorouracil (5-FU), adriamycin, mitomycin and cisplatin. During the late 1970s a FAM (fluorouracil, adriamycin, mitomycin) regimen composed of these active drugs was widely adapted as a routine treatment for advanced gastric cancer, although no controlled trials supported its routine use. In fact, in a comparative study between 5-FU and 5-FU plus adriamycin or FAM, no difference in survival between the treatment groups was observed (Cullinan et al., 1985) .
During the last decade a new, promising cancer regimen has been reported using the technique of biochemical modulation of 5-FU. Klein et al. (1983) developed the regimen of high-dose methotrexate (MTX), high-dose 5-FU and adriamycin with leucovorin rescue, called FAMTX. The first report on this combination described a response rate as high as 63% (Klein et al., 1983 ). Since then, in different studies, a total of 364 patients have received FAMT`X, with a cumulative response rate of 41% (Kelsen et al., 1992) .
Although the response rates using these new drug combinations are considerably higher than with 5-FU alone, no definitive proof exists as to whether these treatments have any real impact on patients' survival, nor does there exist any such study on 5-FU. To elucidate this issue, we performed a randomised tnral in which patients were assigned to receive either chemotherapy (FEMTX) plus trace amounts of vitamin A and E or the same vitamins and best supportive care only. In this study we replaced adriamycin with epirubicin for reasons discussed later. The main focus of this study was to analyse whether this chemotherapy regimen can change the natural course of advanced gastric cancer, thus prolonging patients' survival.
Patients and methods

Patients
During the period from July 1986 to June 1992, 41 patients with histologically confirmed gastric cancer were entered into this study. During the study period five other patients were eligible for this study but refused to take part in the randomisation. The patients were randomised by a sealed envelope method. Random permutated blocks (length 10) were used. Table I . Twelve patients (five in the FEMTX group and seven in the control group) had locally recurrent or metastatic disease after radical operation. The median time (range) from orginal diagnosis to randomisation in the FEMTX and control group, respectively was 67 weeks vs 55 (29-182) weeks in relapsed patients and 7 (1-17) weeks vs 8 (5-13) weeks in newly diagnosed patients. As can be seen, the two groups were well balanced as to the usual prognostic criteria, including age, Karnofsky performance status, weight loss, proportion of symptomatic patients (weight loss was not included as a symptom), extent of disease, metastatic sites and prior surgery. Slightly more male patients were randomised into the FEMTX arm.
Response
In the treatment group 20 patients received at least one course of chemotherapy. One patient never received the study drugs owing to some disturbance of renal function observed after randomisation. The median number of adminiser chemotherapy courses was 5, and at most two patients received up to 12 courses. Among all the randomised patients in the FEMTX arm, there were six responders (29%), four complete and two partial (Table I 
Timeto progression and survival
In the FEMTX group, the median time to progression was 5.4 months (95% CI 3.1-11.7 months) vs only 1.7 months (95% CI 1.2-2.7 months) in the control group (P<0.0013). This difference is illustrated in Figure 1 . Similarly, a highly significant difference (P<0.0006) was detected in median survival between the two study groups. The FEMTX group displayed median survival of 12.3 months (95% CI 7.1-15.6 months), while the control group had a median survival of only 3.1 months (95% CI 1.6-4.6 months). This remarkable difference is shown in Figure 2 . The 1 year survival rate in the treated group was 52%, and the 2 year survival rate was 24%, while 1 and 2 year survival rates were 5% in the control group.
At September 1992, 3 months after the last randomisation, five patients were alive, all of these in the FEMTX group, while all of the control patients had died. A highly significant difference (P<0.001, two-sided) in survivals was detected, favouring the treatment group. Owing to slow patient accrual and the conspicuous difference in patient survival, further randomisation was abandoned at this point. At the close of this analysis, May 1994, two (Table III) which could be better ameliorated during the last 2 years of the study with new antiemetic drugs. Three patients (15%) had fairly disturbing stomatitis, and two of these and a third patient also had peeling of the skin, mainly from palmar and plantar areas. The main haematological toxicity was leucopenia: ten patients (50%) had grade III/IV leucopenia and two (10%) We have carefully analysed all the palliative measures in the two study groups. FEMTX chemotherapy required hospitalisation for 2-3 days every month during the treatment period. Many of the patients had pain at first presentation. In the chemotherapy group pain was either releved or unchanged, while the majority of the control patients experienced aggravation of pain within 2 months. Consequently, the use of analgesics by treated patients was unged or reduced and by control patient was increased. (Wldke et al., 1990; Fmdlay and Cunningham, 1993; Cocconi, 1994; Ellis and Cunningham, 1994) . Some of these CRs have even been confirmed histopathologically.
In spite of promisg high response rates achieved with these drug combinations, it has been unclear until now whether these favourable responses can be translted into prolonged survival. This study was initiated because all previous studis on gastric cancer involving a new drug or drug combination have compared results with results in patients treated with some other drug(s) or drug combination(s). In most of the previous studies the comparison group has comprised patients treated with 5-FU alone. However, there have been no randomised comparative stui on 5-FU relating 'natural' outcome of the disease to that of patients treated with the best supportive care only, without any chemotherapy.
As a treatment schedule, we sekld a slightly modified course of FAMTX, a regimen reported to yield one of the highest response rates. (Wils et al., 1991) . In fact, the International Cooperative Cancer Group (ICCG) is currently using FEMTX as a reference treatment in comparison with FEMTX-P, with the addition of cisplatin (P) (Wils, 1992) . The aim of this study is to evaluate more precsely the role of cisplatin added to this high-dose MTXbsed Previous experiences with FEMTX in gastric cancer are imited to one phase II study with a response rate of 37% (Wils et al., 1990 ). An in vitro study even suggests that in similar concentrations gastric cancer cells may be more sensitive to epirubicin than to adriamycin (Kohnoe et al., 1992) . If this observation could be transferred to a clinical situation, our sekction of epirubicin, with a doubled dose of adriamycin compared with the orginal FAMTX regimen, might offer patients some advantage. Furthermore, using the same drugs with different scheduling also seems to be effective in patients with advanced colorectal cancer (Pyrh6nen and Kouri, 1992) . Although the number of patients in this study is limited, our observations do confirm the fact that sequentially adminliered high-dose MTX and 5-FU, combined with the anthracyclin epidoxorubicin, is a highly active drug combination in advanced gastric cancer, not only in terms of objective responses but also in retarding disease and pain progression and prolonging patients' survival. Unfortunately, this study had to be stopped even before the targeted number (60) of patients was achieved, mainly because of slow patient accrual and the withdrawal of the second original research unit from the study. The analysis, however, made more than 6 years after initiating the study, demonstrated a conspicuous difference in overall survival between the chemotherapytreated group and the control group. It was thus considered unethical to continue this study. This decision was further supported by the fact that all five patients who were alive at that time were in the chemotherapy-treated group, four of these having achieved a complete response as a result of the treatment.
In comparing the response rate of our patients treated with the FEMTX regimen, the results are similar to the combined data on FAMTX. The response rate calculated for all the randomised patiets (including one patient who never received the drugs) m the present study was 29%, while the cumulative response rate for FAMTX involving 364 treated patients has been reported to be 41% (Kelsen et al., 1992) . The median overall survival of the present study, 12.3 months (95% CI 7.1-15.6 months), although slightly longer than in most of the FAMTX studies, was in the same range as in those studies. Nor did the median overall survival of 3.1 months (95% CI 1.6-4.6 months) for the control group differ remariably from expectations of the natural course of advanced gastric cancer without chemotherapy. Historically, in some reports median survival of patients without chemotherapy has been reported to range from 3 to 4 months (Moertel, 1968) . After a detailed comparison, the conclusion is that no difference in patient characteristics or any supportive measure except chemotherapy can explain the difference in survival in the two study groups. Interestingly, a recent study by Murad et al. (1993) demonstrates very similar observations to our results. In that study patients were randomised to a modified version of FAMTX or best supportive care. In the middle of the study the randomisation was also interrupted because of strong evidence of benefit in the treatment arm. Further patients were accrued to the treatment arm, and by the end of the study 30 evaluable patients had recoived chemotherapy and ten supportive treatment only. The median overall survival time of the treated group was 10 months, and that of the control group only 3 months (P = 0.001).
The accumulating data now support the view that in patients with locally advanced or metastatic gastric cancer prolongation of survival can be achieved by treatment with chemotherapy. The particular combination used in this study seems to be of most interest. In a comparative trial by the EORTC study group, treatment with FAMTX resulted in sigificantly longer median survival than and similar toxcity as the widely used FAM regimen (Wlds et a!., 1991). Another study compared FAMTX with a promising regimen EAP (Kelsen et al., 1992) . Randomisation of this study had to be interrupted soon after 60 patients were colleted, 30 in each treatment arm, since the EAP combination demonstrated significantly more severe toxicity, including four treatmentrelated deaths, and the response rate was slightly lower among patients receiving EAP than among those receiving FAMTX.
Although regimens such as FAMTX or FEMTX are still far from the optimum when the aim is cure, they can be used as comparative treatments in new developmental approaches. These combinations should also be further explored in new therapeutic strategies for gastric cancer such as pre- (Kelsen et al., 1994) or perioperative chemotherapy.
